should i take a glp 1 who glp-1 The promise and peril of GLP-1 agonists: What we do (and don't) know as of August 2024 What You Should Know Before
Description
10.1016/j.neuropharm.2011.12.022 64 KeatingG

Exendin-4 Protects Endothelial Cells from Lipoapoptosis by PKA, PI3K, eNOS, P38 MAPK, and JNK Pathways

[DOI] [PubMed] [Google Scholar] 32.Pratley R.E., Aroda V.R., Lingvay I., Ldemann J., Andreassen C., Navarria A., Viljoen A., SUSTAIN 7 Investigators Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): A randomised, open-label, phase 3b trial

For those looking to add exposure now, the smarter move is to wait for the stock to either consolidate cleanly above $1,000 or pull back to the $940$960 support zone before sizing up

1):S1S4

No, GLP-1 receptor agonists are not currently licensed for NAFLD treatment in the UK
